First Time Loading...

Entrada Therapeutics Inc
NASDAQ:TRDA

Watchlist Manager
Entrada Therapeutics Inc Logo
Entrada Therapeutics Inc
NASDAQ:TRDA
Watchlist
Price: 14.36 USD 2.21% Market Closed
Updated: May 10, 2024

Entrada Therapeutics Inc
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Entrada Therapeutics Inc
Selling, General & Administrative Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Entrada Therapeutics Inc
NASDAQ:TRDA
Selling, General & Administrative
-$32.3m
CAGR 3-Years
-80%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Selling, General & Administrative
-$12.7B
CAGR 3-Years
-4%
CAGR 5-Years
-11%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Selling, General & Administrative
-$6.1B
CAGR 3-Years
-6%
CAGR 5-Years
-8%
CAGR 10-Years
-13%
Amgen Inc
NASDAQ:AMGN
Selling, General & Administrative
-$6.7B
CAGR 3-Years
-6%
CAGR 5-Years
-5%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Selling, General & Administrative
-$1.1B
CAGR 3-Years
-14%
CAGR 5-Years
-15%
CAGR 10-Years
-12%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Selling, General & Administrative
-$2.7B
CAGR 3-Years
-25%
CAGR 5-Years
-12%
CAGR 10-Years
-23%

See Also

What is Entrada Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-32.3m USD

Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Selling, General & Administrative amounts to -32.3m USD.

What is Entrada Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 3Y
-80%

Over the last year, the Selling, General & Administrative growth was -5%. The average annual Selling, General & Administrative growth rates for Entrada Therapeutics Inc have been -80% over the past three years .